VitalConnect
The company plans to use the funding to expand its commercial team, scale operations and develop new products.
The device continuously monitors four significant vital signs: heart rate, heart rate variability, respiratory rate and activity.
The continuous remote monitor can help prevent complications driven by experimental COVID-19 treatments such as hydroxychloroquine or chloroquine, according to the agency.